Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enrica Mezzalana

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2026
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I dataMaddlie Bardol, Andrea Henrich, Celine Sarr, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2018
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issuesSilvia Maria Lavezzi, Enrica Mezzalana, Stefano Zamuner, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2015
Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static cultureKevin R Page, Enrica Mezzalana, Alexander J MacDonald, et al.
Pharmaceutics|December 11, 2020
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and CaffeineTobias Kanacher, Andreas Lindauer, Enrica Mezzalana, et al.
The AAPS Journal|June 22, 2011
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysisRoberto Bizzotto, Stefano Zamuner, Enrica Mezzalana, et al.
Clinical and Translational Science|December 28, 2021
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetesYoshiko Tomita, Emma Hansson, Florent Mazuir, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Pharmacokinetics and Pharmacodynamics|January 6, 2026
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I dataMaddlie Bardol, Andrea Henrich, Celine Sarr, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 12, 2018
MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issuesSilvia Maria Lavezzi, Enrica Mezzalana, Stefano Zamuner, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2015
Temporal pharmacokinetic/pharmacodynamic interaction between human CD3ε antigen-targeted monoclonal antibody otelixizumab and CD3ε binding and expression in human peripheral blood mononuclear cell static cultureKevin R Page, Enrica Mezzalana, Alexander J MacDonald, et al.
Pharmaceutics|December 11, 2020
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and CaffeineTobias Kanacher, Andreas Lindauer, Enrica Mezzalana, et al.
The AAPS Journal|June 22, 2011
Multinomial logistic functions in markov chain models of sleep architecture: internal and external validation and covariate analysisRoberto Bizzotto, Stefano Zamuner, Enrica Mezzalana, et al.
Clinical and Translational Science|December 28, 2021
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetesYoshiko Tomita, Emma Hansson, Florent Mazuir, et al.
British Journal of Clinical Pharmacology|December 20, 2018
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patientsGeorgios Vlasakakis, Antonella Napolitano, Ruth Barnard, et al.
Pageof 1